Tweet Tracking: A Must For Companies’ Adverse Event Oversight?
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory experts disagree on how actively device and drug companies should be monitoring social media sites for information on adverse events.
You may also be interested in...
FDA’s Social Media Guidance: As Industry Waits, How Watchful Should It Be?
In the absence of clear policy from the agency, GSK keeps careful eyes on Facebook, but experts disagree on the extent to which drug companies are required to actively monitor social media sites.
Off-Label Questions, Online: FDA Explains How To Handle Them
FDA draft guidance weighs in on web communications, saying that firms must answer off-label-information questions privately, even if the questions arise in a public online forum.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.